JAPANESE COHORT STUDY OF FIRST LINE CHEMOTHERAPY (CT) FOR METASTATIC COLORECTAL CANCER (MCRC) CONTAINING FLUOROPYRIMIDINE, OXALIPLATIN AND BEVACIZUMAB: EMERALD STUDY, FIRST REPORT

被引：0
|
作者：
Taku, K. [1 ]
Ohata, K. [1 ]
Yamazaki, K. [2 ]
Nishikawa, G. [1 ]
Watanabe, M. [3 ]
Sato, S. [3 ]
Oshima, T. [3 ]
Hirano, H. [1 ]
Amano, T. [4 ]
Ohashi, Y. [5 ]
机构：
[1] Shizuoka Prefectural Gen Hosp, Div Med Oncol, Shizuoka, Japan
[2] Shizuoka Canc Ctr, Shizuoka, Japan
[3] Shizuoka Prefectural Gen Hosp, Div Surg, Shizuoka, Japan
[4] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido, Japan
[5] Univ Tokyo, Sch Publ Hlth, Dept Biostat, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：220 / 220
页数：1
相关论文
共 50 条
  • [1] Japanese cohort study of first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) containing fluorouracil, oxaliplatin, and bevacizumab: EMERaLD study, first report
    Taku, Keisei
    Ohata, Kou
    Amano, Toraji
    Ohashi, Yasuo
    Yamazaki, Kentaro
    Watanabe, Masaya
    Satou, Shinsuke
    Ooshima, Takeshi
    Nishikawa, Go
    Hirano, Hidekazu
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [2] A Japanese cohort study of first-line chemotherapy for metastatic colorectal cancer: The EMERaLD study
    Takeda, K.
    Amano, T.
    Ohashi, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S358 - S358
  • [3] Japanese cross-sectional cohort study of 1st line chemotherapy (CT) for metastatic colorectal cancer (mCRC) (EMERaLD study)
    Maeda, A.
    Amano, T.
    Ohashi, Y.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S558 - S558
  • [4] Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer
    Liu, Jia
    Wang, Biao
    Fang, Wentong
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2020, 27 (05) : 267 - 270
  • [5] Safety, tolerability and efficacy of the addition of bevacizumab to oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer (mCRC): Results of TREE 2 cohort of the TREE study
    Hochster, H.
    Hart, L.
    Ramanathan, R. K.
    Hainsworth, J.
    Griffing, S.
    Mass, R.
    Nagarwala, Y.
    Jirau-Lucca, G.
    Shpilsky, A.
    Childs, B. H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 173 - 173
  • [6] Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer (mCRC): Final analysis of the TREE-Study.
    Hochster, H. S.
    Hart, L. L.
    Ramanathan, R. K.
    Hainsworth, J. D.
    Hedrick, E. E.
    Childs, B. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 148S - 148S
  • [7] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
    Grapsa, Dimitra
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1267 - 1281
  • [8] Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: Results of the TREE study
    Hochster, Howard S.
    Hart, Lowell L.
    Ramanathan, Ramesh K.
    Childs, Barrett H.
    Hainsworth, John D.
    Cohn, Allen L.
    Wong, Lucas
    Fehrenbacher, Louis
    Abubakr, Yousif
    Saif, M. Wasif
    Schwartzberg, Lee
    Hedrick, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) : 3523 - 3529
  • [9] Phase I/II study of novel oral fluoropyrimidine S-1 in combination with oxaliplatin (SOX) as first-line chemotherapy for metastatic colorectal cancer (mCRC)
    Tahara, M.
    Yamada, Y.
    Ohtsu, A.
    Shirao, K.
    Shimada, Y.
    Sasaki, Y.
    Yamamoto, W.
    Satoh, T.
    Okamoto, W.
    Tanigawara, Y.
    EJC SUPPLEMENTS, 2007, 5 (04): : 254 - 254
  • [10] First-line bevacizumab (REV) and chemotherapy (CT) for metastatic colorectal cancer (mCRC); Results from a developing nation
    Franke, F. A.
    Azevedo, S. J.
    Gampel, O.
    Guimaraes, J. Q.
    Schaum, M. R.
    Murad, A.
    Coutinho, A. K.
    Oliveira, J. A.
    Matos Neto, J. N.
    Franca, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345